Until recently, treatment of childhood-onset Type 2 diabetes mellitus has been limited to metformin and insulin, however, new drugs approved for use in pediatric Type 2 diabetes mellitus such as glucagon-like peptide (GLP-1) agonists show promise [34]. This evidence concerns the gene INS and diabetes mellitus.